BR0312474A - Partìcula viral adjuvante - Google Patents

Partìcula viral adjuvante

Info

Publication number
BR0312474A
BR0312474A BR0312474-6A BR0312474A BR0312474A BR 0312474 A BR0312474 A BR 0312474A BR 0312474 A BR0312474 A BR 0312474A BR 0312474 A BR0312474 A BR 0312474A
Authority
BR
Brazil
Prior art keywords
vlp
protein
viral particle
immunogen
particle
Prior art date
Application number
BR0312474-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Denis Leclerc
Nathalie Majeau
Philippe Tessier
Constantino Rober Lopez-Macias
Original Assignee
Denis Leclerc
Nathalie Majeau
Philippe Tessier
Constantino Rober Lopez-Macias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denis Leclerc, Nathalie Majeau, Philippe Tessier, Constantino Rober Lopez-Macias filed Critical Denis Leclerc
Publication of BR0312474A publication Critical patent/BR0312474A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR0312474-6A 2002-07-05 2003-06-30 Partìcula viral adjuvante BR0312474A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39365902P 2002-07-05 2002-07-05
PCT/CA2003/000985 WO2004004761A2 (en) 2002-07-05 2003-06-30 Adjuvant viral particle

Publications (1)

Publication Number Publication Date
BR0312474A true BR0312474A (pt) 2005-04-26

Family

ID=30115621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312474-6A BR0312474A (pt) 2002-07-05 2003-06-30 Partìcula viral adjuvante

Country Status (14)

Country Link
US (2) US7641896B2 (OSRAM)
EP (2) EP1523329B1 (OSRAM)
JP (1) JP4953570B2 (OSRAM)
KR (1) KR20050044886A (OSRAM)
CN (1) CN1665528B (OSRAM)
AU (1) AU2003281246A1 (OSRAM)
BR (1) BR0312474A (OSRAM)
CA (1) CA2434000C (OSRAM)
DK (1) DK1523329T3 (OSRAM)
ES (1) ES2431963T3 (OSRAM)
MX (1) MXPA05000287A (OSRAM)
NO (1) NO20050396L (OSRAM)
PT (1) PT1523329E (OSRAM)
WO (1) WO2004004761A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CN1665528B (zh) * 2002-07-05 2013-05-15 弗利亚生物技术公司 佐剂病毒颗粒
MX2007003171A (es) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
EP1809335A2 (en) 2004-10-25 2007-07-25 Cytos Biotechnology AG Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
KR100688522B1 (ko) * 2005-01-18 2007-03-02 삼성전자주식회사 영상데이터 압축기 및 압축방법
CN101287489A (zh) * 2005-06-01 2008-10-15 陶氏环球技术公司 多价病毒样颗粒的生产
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
WO2012048430A1 (en) * 2010-10-14 2012-04-19 Folia Biotech Inc. Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof
US20100047264A1 (en) * 2006-11-15 2010-02-25 Folia Biotech Inc. Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof
MX2009007942A (es) * 2007-01-26 2010-06-01 Folia Biotech Inc Vacunas basadas en virus del mosaico de la papaya contra salmonella typhi y otros patogenos enterobacterianos.
CA2685308A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
US20110104191A1 (en) * 2007-09-11 2011-05-05 Universite Laval Malva mosaic virus and virus-like particles and uses thereof
US20110189231A1 (en) * 2008-06-17 2011-08-04 Denis Leclerc Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
US20130236491A1 (en) * 2010-12-09 2013-09-12 Iosif Grigorievich Atabekov Spherical nano and microparticles derived from plant viruses for the display of foreign proteins or epitopes
US20140154288A1 (en) 2011-05-13 2014-06-05 Folia Biotech Inc. Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
HUE042761T2 (hu) 2011-06-09 2019-07-29 Biomay Ag Peptidhordozó fúziós fehérjék allergia-oltóanyagként
JP2015514097A (ja) * 2012-04-02 2015-05-18 フォリア バイオテック インコーポレイテッド 組換えパパイヤモザイクウイルスコートタンパク質およびインフルエンザワクチンにおけるその使用
WO2015039255A1 (en) * 2013-09-19 2015-03-26 Folia Biotech Inc. Papaya mosaic virus and virus-like particles in cancer therapy
US20180153984A1 (en) * 2015-04-30 2018-06-07 The Regents Of The University Of California Adjuvant particles comprising adenosine receptor antagonists
CN115956125A (zh) * 2020-03-31 2023-04-11 医学噬菌体生物制药公司 用于产生病毒样颗粒的载体及其用途
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79880A0 (en) 1985-08-29 1986-11-30 Inst Medical W & E Hall Recombinant virus
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
CA2089497A1 (en) * 1990-08-15 1992-02-16 Lendon Payne Self-assembling replication defective hybrid virus particles
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
WO1996012027A1 (en) 1994-10-18 1996-04-25 Scottish Crop Research Institute Method of producing a chimeric protein
GB9607899D0 (en) 1996-04-17 1996-06-19 Scottish Crop Research Inst Virus-like particle
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
CA2288129A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19752855C2 (de) * 1997-11-28 2003-04-03 Bundesrepublik Deutschland Let Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
FR2786773B1 (fr) 1998-12-03 2002-03-08 Univ Paris Curie Proteines d'enveloppe, methodes et utilisations
EA004497B1 (ru) * 1998-12-04 2004-04-29 Байоджен, Инк. Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
DE19904800C1 (de) * 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB9924352D0 (en) 1999-10-14 1999-12-15 Hellendoorn Koen Methods,compositions and applications relating to the generation of novel plant viral particles
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
AUPQ661600A0 (en) 2000-03-31 2000-05-04 Macfarlane Burnet Centre For Medical Research Limited, The A nucleic acid construct and methods related thereto
IT1317046B1 (it) 2000-06-16 2003-05-26 Ist Superiore Sanita Proteina di fusione, particelle virali chimeriche che la espongono sulcapside, piante infettate con tali particelle, loro usi e composizioni
AU2001270164A1 (en) 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
US7279306B2 (en) 2000-07-06 2007-10-09 Georgetown University Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof
GB0028319D0 (en) * 2000-11-20 2001-01-03 Univ Southampton Materials and methods relating to fusion proteins for inducing an immune response
ITRM20010332A1 (it) * 2001-06-11 2002-12-11 Ist Superiore Sanita Vaccini a subunita' e procedimenti per la loro produzione.
US8101189B2 (en) * 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CN1665528B (zh) * 2002-07-05 2013-05-15 弗利亚生物技术公司 佐剂病毒颗粒

Also Published As

Publication number Publication date
ES2431963T3 (es) 2013-11-28
AU2003281246A1 (en) 2004-01-23
HK1075214A1 (en) 2005-12-09
EP1523329B1 (en) 2013-07-24
EP2272525A3 (en) 2011-11-16
US7641896B2 (en) 2010-01-05
PT1523329E (pt) 2013-10-08
US20090280145A1 (en) 2009-11-12
MXPA05000287A (es) 2005-09-08
WO2004004761A3 (en) 2004-05-06
CN1665528B (zh) 2013-05-15
CA2434000A1 (en) 2004-01-05
JP4953570B2 (ja) 2012-06-13
JP2006504644A (ja) 2006-02-09
EP1523329A2 (en) 2005-04-20
EP2272525A2 (en) 2011-01-12
US8282940B2 (en) 2012-10-09
DK1523329T3 (da) 2013-10-14
CA2434000C (en) 2012-07-17
KR20050044886A (ko) 2005-05-13
WO2004004761A2 (en) 2004-01-15
US20050048082A1 (en) 2005-03-03
CN1665528A (zh) 2005-09-07
NO20050396L (no) 2005-01-25

Similar Documents

Publication Publication Date Title
BR0312474A (pt) Partìcula viral adjuvante
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
DK1185660T3 (da) Svinecircovirus-vaccine i rekombinant poxvirus
ECSP045300A (es) Antígenos virales
BRPI0210076A8 (pt) Preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato
MXPA05009580A (es) Vacuna contra el virus de la influenza.
BR9814487A (pt) "vacina"
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
WO2005118626A3 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
BR0204470A (pt) Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
ATE352557T1 (de) Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
ATE267256T1 (de) Hepatis e-virus antigene und dessen verwendungen
WO2021202599A3 (en) Adeno-associated virus based compositions and related methods for inducing humoral immunity
BR0112020A (pt) Partìculas tipo vìrus de bvdv
BR112022001070A2 (pt) Composição de imunogenicidade polivalente para papilomavírus humano
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired